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Clinical and left ventricular function outcomes 
up to five years after dynamic cardiomyoplasty 
Improvement in congestive heart failure and left ventricular function after dynamic ardiomyoplasty 
has been reported in patients with severe cardiomyopathies, but the long-term effects of this 
procedure remain unclear. In this investigation 31 patients undergoing cardiomyoplasty for 
treatment of idiopathic dilated cardiomyopathy were annually investigated with radionuclide 
scintigraphy, Doppler echocardiography, and right-sided heart catheterization. They were in New 
York Heart Association functional class IH or IV before the operation. No hospital deaths occurred, 
but one patient with progressive heart failure required urgent heart transplantation 42days after 
cardiomyoplasty. The other patients were followed up from 6 to 70 months (mean 25.6 months) and 
12 patients died at late follow-up. Actuarial survivals were 86% at 1 year, 61.4% at 2 years, and 42.5% 
at 3 to 5 years of follow-up. Multivariate analysis of factors influencing outcome showed that 
long-term survival was significantly affected by preoperative functional class and pulmonary 
vascular esistance. Functional class improved from 3.2 - 0.4 to 1.7 -+ 0.7 in the surviving patients 
(p < 0.01). Furthermore, left ventricular ejection fraction improved from 19.8% -+ 3% to 23.9% _ 
7.2% (p < 0.01), and significant changes in stroke index, arterial pressure, pulmonary wedge 
pressure, and left ventricular stroke work index were also found at 6 months of foflow-up. In the late 
postoperative period, the left ventricular ejection fraction tended to decrease and returned to 
preoperative l vels at 5 years, whereas hemodynamic variables did not change significantly. Thus, 
despite the tendency of the left ventricular ejection fraction to decrease at late follow-up, the 
long-term course of these patients eems to be characterized by the maintenance of hemodynamic 
improvement. However, long-term survival after cardiomyoplasty is limited by the severity of the 
patient's condition before the operation. (J THORAC CARDIOVASC SURG 1995;109:353-63) 
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Dynamic  cardiomyoplasty has been proposed by 
several authors as an alternative to heart transplan- 
tation in the treatment of patients with severe 
From the Instituto do Cora~io da Faculdade de Medicina da 
Universidade  S~o Paulo, Silo Paulo, Brazil. 
Supported by grant 521/88/55 from Fundaqio E. J. Zerbini, Silo 
Paulo, Brazil. 
Read at the Seventy-fourth Annual Meeting of The American 
Association for Thoracic Surgery, New York, N.Y., April 
24-27, 1994. 
Address for reprints: Luiz Felipe P. Moreira, MD, Divisio de 
Cirurgia, Instituto do Coragio, Av. Dr. En6as C. Aguiar, 
44~Sio Paulo, SP, Brazil, CEP: 05403-000. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $3.00 + 0 12/6/60458 
cardiomyopathies. 1-9 Its primary objectives are to 
reverse congestive heart failure and to halt the 
progression of the underlying disease by the in- 
crease of ventricular pumping performance and by 
the reinforcement of ventricular walls. 
Improvement in congestive heart failure and left 
ventricular function were demonstrated after car- 
diomyoplasty in patients with dilated or ischemic 
cardiomyopathies. 1-9 Initial results also suggest hat 
this procedure may improve long-term survival in 
patients with advanced heart failure. 1' a0 Neverthe- 
less, potential imitations and risk factors of poor 
cardiomyoplasty outcome have been further eport- 
ed.l-5, 9 In addition, the absence of previous tudies 
about long-term changes in left ventricular function 
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after this surgical procedure has precluded efinitive 
conclusions about its value. 
The purpose of this report is to document he 
clinical and left ventricular function effects of dy- 
namic cardiomyoplasty up to 5 years of follow-up in 
patients with advanced heart failure caused by idio- 
pathic dilated cardiomyopathy. The preoperative 
factors influencing the outcome are also analyzed. 
Patients and methods 
Study population. From May 1988 to November 1993, 
31 patients with idiopathic dilated cardiomyopathy were 
treated by dynamic ardiomyoplasty at the Heart Institute, 
University of Silo Paulo Medical School. Their ages 
ranged from 28 to 62 years (mean 48.2 years); 23 were 
men and eight were women. Twenty-four patients were in 
New York Heart Association functional class III and 
seven were in class IV despite maximal medical therapy 
with digitalis, diuretics, and angiotensin-converting e - 
zyme inhibitors. They also had had an average of 2.6 
hospitalizations for treatment of congestive heart failure 
in the year preceding the operation. Five of these patients 
had reversible cardiogenic shock with temporary use of 
intravenous inotropic drugs. 
All patients had a left ventricular ejection fraction 
below 30%, as documented atradioisotopic scintigraphy, 
and had high left ventricular filling pressures at heart 
catheterization (mean pulmonary wedge pressure or left 
ventricular end-diastolic pressure above 15 mm Hg). The 
absence of significant coronary artery compromise and 
diffuse, severe left ventricular dilatation were also dem- 
onstrated by heart catheterization in every patient. Mitral 
valve insufficiency was present in 24 patients, being mod- 
erate in five and mild in 19 patients. 
Twenty-seven patients were in sinus rhythm and the 
remaining four were in atrial fibrillation. Holter monitor 
recordings also showed that 12 patients had more than 50 
premature ventricular contractions per hour and that 15 
patients had several episodes of nonsustained ventricular 
tachycardia. Standard spirometric study documented mild 
restrictive compromise ofventilatory function in 26 patients. 
In the present investigation, patients receiving intrave- 
nous inotropic drugs were not candidates for cardiomyo- 
plasty. Furthermore, important or severe valvular dysfunc- 
tion, arrhythmias not controlled by medical therapy, and 
pulmonary or multiple organ diseases were also consid- 
ered contraindications for this operation. 
Medical or psychosocial contraindications to heart 
transplantation were present in most of these patients. All 
patients igned a special informed consent form according 
to the Scientific Committee of the Heart Institute. 
Surgical technique. Dynamic ardiomyoplasty was per- 
formed without extracorporeal circulation by means of 
two separate incisions: a lateral approach for muscle flap 
dissection and a subsequent median sternotomy for car- 
diac access. Dissection and transposition of the left latis- 
simus dorsi muscle followed the technique described by 
Carpentier and associates) 1 The skeletal muscle flap was 
then wrapped around the ventricular surfaces and fixed 
directly to the myocardium by separated sutures, provid- 
ing a left posterior cardiocostal wrapping. 6 Two intramus- 
cular pacing electrodes (Medtronic SP 5528, Medtronic, 
Inc., Minneapolis, Minn.) were implanted in the skeletal 
muscle graft and an intramyocardial sensing lead (Medtronic 
SP 5548) was placed in either the right or left ventricle. The 
cardiomyostimulator Medtronic SP 1005 was used for mus- 
cle flap stimulation. 
Anesthetic management of cardiomyoplasty included 
the systematic use of dopamine, dobutamine, and sodium 
nitroprusside, associated with the maintenance of ade- 
quate volume loading, to improve the hemodynamic pro- 
file and to stabilize arterial blood pressure ven while the 
heart was being wrapped in muscle. 12 The prophylactic 
use of intravenous inotropic support was continued for at 
least I week after the operation. 
Muscle flap stimulation. Skeletal muscle flap stimula- 
tion started 2weeks after the operation, and a progressive 
muscle conditioning protocol was followedJ 1 In the late 
postoperative p riod, the muscle flap was paced in 1:1 or 
1:2 synchrony with the heart rate. Pulse train stimulation 
was used with a burst frequency of 30 Hz and was 
associated with supramaximal pulse amplitude values to 
avoid ineffective muscle flap contraction. The delay be- 
tween the ventricular sensed event and the muscle burst 
was adjusted to provide an exact synchronization between 
muscle flap contraction and ventricular systole under 
echocardiographic monitoring. 6 
Follow-up protocol. Ventricular function was evaluated 
in all patients before the operation, at 6 months of 
follow-up, and annually until the fifth postoperative y ar 
by means of Doppler echocardiography, radioisotopic 
angiography, and right-sided heart catheterization. 
Doppler echocardiography was performed with the 
Aloka SSD-730 and SSD-870 sector scans (Aloka Inc., 
Tokyo, Japan). A 2.5 MHz transducer was used for 
M-mode and two-dimensional studies, whereas a 2 MHz 
transducer was used for Doppler determinations. The 
standard parameters of left ventricular function (left 
ventricular end-diastolic diameter, left ventricular end- 
systolic diameter, and left ventricular segmental wall 
shortening) were obtained by M-mode and two-dimen- 
sional echocardiograms. Left ventricular stroke volume 
and the degree of mitral valve insufficiency were deter- 
mined by Doppler analysis. 
Radioisotopic scintigraphy was obtained after intrave- 
nous injection of technetium 99m. Gated blood pool 
imaging was obtained in the left anterior oblique position 
with a Siemens model LEM+ camera (Siemens Corp., 
Union, N.J.). The images were analyzed in a Microvax 
model 3300 computer (Siemens): left and right ventricular 
ejection fractions were calculated. 
For right-sided heart catheterization, a thermodilution 
balloon-tipped catheter was positioned in the pulmonary 
artery. Pressures were measured with a strain gauge 
transducer, whereas cardiac output was obtained by the 
thermodilution technique. Arterial pressures were mea- 
sured by noninvasive standard means. Cardiac index, 
stroke index, left and right ventricular stroke work in- 
dexes, and vascular esistances were calculated by stan- 
dard formulas. 
Statistical analysis. Cumulative mortality rates over 
time were determined by the actuarial method, and 
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differences between them were assessed by the log-rank 
test. Repeated-measures analysis of variance was used to 
compare data obtained before and after cardiomyoplasty. 
Ap value less than 0.05 was considered significant. Data 
are presented as mean plus or minus tandard eviation, 
whereas urvival rates are presented as mean plus or 
minus tandard error of the mean. 
So that the association fvariables to survival could be 
assessed, univariate analysis was performed by means of 
the unpaired Student's t test and Fisher's exact est. 
Variables with a p value less than 0.10 in univariate 
analysis were entered into the Cox proportional-hazards 
regression model. Patients with less than 1 year of fol- 
low-up were excluded from this analysis and patients 
undergoing urgent heart ransplantation after cardiomyo- 
plasty were included as deaths. 
Results 
Immediate surgical results. No intraoperative or 
hospital deaths occurred in this series. Three pa- 
tients required countershock for ventricular fibrilla- 
tion while the heart was being wrapped with muscle. 
The immediate postoperative course was un- 
eventful in general. One patient had low cardiac 
output despite prophylactic pharmacologic support 
and required intraaortic balloon counterpulsation. 
A transient period of renal failure and mesenteric 
ischemia developed in another patient. Four pa- 
tients had transitory atrial fibrillation or flutter and 
two patients had pulmonary complications. 
Muscle flap ischemic ompromise was monitored 
by variations in the serum level of creatine kinase 
enzyme, which showed a mean peak value of 946 _+ 
582 IU. Four patients had peak values of creatine 
kinase greater than 1500 IU, and these patients had 
poor muscle flap contraction at the beginning of the 
muscle stimulation protocol. 
During the muscle conditioning period one pa- 
tient had progressive heart failure and successfully 
underwent urgent heart transplantation 42 days 
after the cardiomyoplasty. Another patient died at 2 
months of severe pulmonary thromboembolism and 
infection after having been discharged from the 
hospital. 
Long-term follow-up. Twenty-nine patients com- 
pleted the muscle conditioning protocol, and they 
were followed up from 6 to 70 months (mean 25.8 
months). In the first 19 patients, the muscle flap 
pacing was usually synchronized in a 1:1 mode with 
the heart rate. In the remaining 10 patients, the 
muscle flap was normally paced in a 1:2 mode. 
At 6 months of follow-up, New York Heart 
Association functional class improved from 3.2 + 
0.4 to 1.7 _+ 0.7 (p < 0.01). The number of hospi- 
talizations during the follow-up period significantly 
decreased to 0.6 per patient per year (p < 0.01). 
On the other hand, 11 other patients died at 
long-term follow-up. The cause of death was pro- 
gressive heart failure in seven patients, and four 
patients died suddenly. Progressive heart failure was 
associated with pulmonary complications in four 
patients and with renal failure, cerebral vascular 
accident, or myocarditis in the remaining three. The 
actuarial survival curve represented in Fig. i shows 
survivals of 86% + 6.4% at 1 year, 61.4% _+ 10% at 
2 years, and 42.5% + 11.8% from 3 to 5 years of 
follow-up. 
Seven of the surviving patients are currently in 
functional class I, eight in class II, and two in class 
III, some of them using fewer drugs or lower doses 
than they did in the preoperative period. Another 
patient who had progressive heart failure also un- 
derwent heart transplantation at 22 months of fol- 
low-up. 
Univariate analysis of preoperative risk factors 
showed that functional c ass IV and elevated pulmo- 
nary vascular esistance were associated with unfa- 
vorable outcome (Table I). When multivariate anal- 
ysis was performed, only preoperative functional 
class was identified as a significant predictor of 
survival (p < 0.01). The survival curves according to 
the preoperative functional c ass are depicted in Fig. 
2. 
Ventricular function evaluation. Data obtained 
by Doppler echocardiography areshown in Table II. 
Significant improvements of left ventricular wall 
shortening and left ventricular stroke volume were 
found at 6 months of follow-up. Otherwise, left 
ventricular wall shortening tended to decrease after 
the first year of follow-up, whereas left ventricular 
stroke volume maintained the improvement re- 
corded at 6 months up to 5 years after cardiomyo- 
plasty. Doppler echocardiographic studies also 
showed that the degree of mitral insufficiency did 
not change in the late follow-up period. 
Right and left ventricular ejection fraction data 
obtained by radioisotopic scintigraphy are also de- 
picted in Table II. Left ventricular ejection fraction 
improved early after the cardiomyoplasty from 
19.8% + 3% to 23.9% _+ 7.2% (p < 0.01). Never- 
theless, this parameter also tended to decrease at 
late follow-up and returned to the preoperative 
levels at 5 years, as shown in Fig. 3. 
The hemodynamic evaluation showed that signif- 
icant improvements of arterial pressure, stroke in- 
dex, and left ventricular stroke work index were 
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Fig. 1. Actuarial survival curve after dynamic ardiomyoplasty. Numbers in parentheses indicate patients 
who completed the follow-up eriod. Values are presented as mean -+ standard error of the mean. 
Table I. Unifactorial analysis of factors associated 
with outcome 
Parameter Significance 
Functional class (NYHA) p = 0.005 
Pulmonary vascular esistance p = 0.028 
Mean pulmonary artery pressure p = 0.096 
Systolic index p = 0.144 
Systemic vascular esistance p = 0.165 
Cardiothoracic ratio p = 0.168 
Mean right atrial pressure p = 0.179 
Mean pulmonary wedge pressure p = 0.309 
Left ventricular end-diastolic pressure p = 0.358 
Cardiac index p = 0.381 
Left ventricular diastolic diameter p = 0.485 
Right ventricular ejection fraction p = 0.579 
NYHA, New York Heart Association. 
associated with significant decreases in pulmonary 
artery pressure and pulmonary wedge pressure at 6 
months of follow-up (Table III). In the late postop- 
erative period, this study showed that the hemody- 
namic benefits of cardiomyoplasty persisted for up 
to 5 years of follow-up. Mean pulmonary wedge pres- 
sures are depicted in Fig. 4, and left ventricular stroke 
work index calculations are presented in Fig. 5. 
Discussion 
The present investigation showed that the long- 
term course of patients with idiopathic dilated car- 
diomyopathy who underwent cardiomyoplasty was 
characterized by the maintenance of the hemody- 
namic improvement oted early after the operation. 
This improvement was maintained espite the ten- 
dency of left ventricular ejection fraction to de- 
crease to preoperative l vels at late follow-up. 
Otherwise, long-term survival after cardiomyo- 
plasty was limited by the severity of the patient's 
condition before the operation. Thus this procedure 
should be used in patients with some degree of 
myocardial functional reserve and without severe 
pulmonary hypertension. In this regard, cardiomyo- 
plasty was performe d in this series without hospital 
mortality and it did not preclude heart transplanta- 
tion, as also described by others. 1' 13 Furthermore, 
the shortage of donors and the increasing number of 
candidates requiring urgent treatment have de- 
creased the number of heart transplants for outpa- 
tient candidates. TM 15 This situation justifies the use 
of alternative surgical options for patients with 
moderate or severe cardiomyopathies who cannot 
have a reasonable quality of life and prognosis on 
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Fig. 2. Actuarial survival curves after dynamic cardiomyoplasty for patients operated in New York Heart 
Association functional classes III (F.C. III) or IV (F.C. IV). Numbers in parentheses indicate patients who 
completed the follow-up eriod. 
Table II. Noninvasive valuation of ventricular function 
Follow-up 
Preop 6 mo 12 mo 24 mo 36 mo 48 mo 60 mo 
(n =28) (n =28) (n=22) (n =11) (n =6) (n =6) (n =4) 
Doppler echocardiography 
LVDD (ram) 73.1 -+ 6.1 73.6 -+ 7.7 73.8 + 7.7 73.7 -+ 3.1 75.7 -+ 5.1 76.3 _+ 4.7 77.5 _+ 6.7 
LVSWS (%) 11.9 + 1.9 15.5 _+ 2.9* 14.7 + 3.5* 13.8 + 3.3 13.2 + 1.9 11.3 _+ 2 11.7 _+ 1.9 
LVSV (ml) 27.3 _+ 9.1 33.5 -4- 11.4" 37.8 _+ 11.8" 36.4 _+ 12" 39.3 + 10.8 35 _+ 15.1 34 + 13.1 
Radioisotopic scintigraphy 
LVEF (%) 19.7 -+ 3.3 23.9 _+ 6.6* 23.3 _+ 6.5* 23.3 _4- 6.2 22.5 .+ 3.6 20.8 _+ 3 20.5 _+ 3.6 
RVEF (%) 25.8 -+ 7.7 24.9 + 8.6 26.5 _+ 8.1" 27.5 -+ 7.3* 26.5 .+ 5.4 26.2 .+ 4.4 25.5 _+ 5.7 
LVDD, Left ventricular diastolic diameter; LVSWS, left ventficular segmental wall shortening; LVSV, left ventricular stroke volume; LVEF, left ventricular 
ejection fraction; RVEF, right ventricutar ejection fraction. Numbers in parentheses indicate the patients evaluated at each period. 
*p < 0.05 in relation to preoperative data of matched patients. 
medical therapy for heart failure. This population 
currently represents more than 2200 patients await- 
ing transplantation in the United States alone, with 
only a 4% chance of receiving aheart each month. 15 
Ventricular function changes. Several authors 
have demonstrated the improvement of left ventric- 
ular ejection fraction after dynamic cardiomyo- 
plasty.X, 4, 8, 9 In a recent report, our group 16 showed 
that this improvement occurs from a global modifi- 
cation of left ventricular regional wall motion and 
may be associated with significant changes in the left 
ventricular shape. Also important is the fact that the 
same study 16 and other reports 1'6 demonstrated the 
decrease of left ventricular ejection fraction when 
the cardiomyostimulator was turned off for several 
hours, which ruled out the possibility of a placebo 
effect. 
Besides ejection fraction changes, selection of 
patients with severe impairment of ventricular func- 
tion and pulmonary hypertension i the current 
investigation was advantageous forshowing the ben- 
eficial hemodynamic effects of cardiomyoplasty, as 
358 Moreira et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1995 
30 
10 
0 
% 
• • • • 
• • • • 
• . ~ m ~ _ _  ~ i • • 
• . • ~ • 
I . _, l i 
• • • 
• • • • • 
• • • • 
• • • 
• • 
I I 1 I I I I 
PREOP. 6 12 24 36 48 60 
MONTHS OF FOLLOW-UP 
Fig. 3. Plots of left ventricular ejection fraction values obtained by radioisotopic scintigraphy in the 
preoperative period and up to 60 months after dynamic ardiomyoplasty. The solid line indicates the 
postoperative trend. 
Table III. Hemodynamic evaluation 
Follow-up 
Preop 6 mo 12 mo 24 mo 36 mo 48 mo 60 mo 
(n = 28) (n = 28) (n = 22) (n = 11) (n = 6) (n = 6) (n = 4) 
MRAP (mrn Hg) 9 ± 3.6 9.1 _+ 5.3 8.9 -+ 5.2 9.1 _+ 6.3 6.7 + 5.6 7.2 __ 5.6 8 +- 4.7 
MPAP (mm Hg) 36.1 ± 11.2 29.8 ± 9.6* 30.3 ± 9.4* 29.8 ± 11.1" 24 ± 6.8 28.2 _ 8.4 30.5 ± 7.5 
MPWP (mm Hg) 24.7 ± 6.3 18.5 ± 6* 18.2 ± 5.8* 17.9 +_ 7.7* 15.2 _+ 3.2* 15.5 ± 6.1 19 ± 6.6 
MAP (mm Hg) 86.1 ± 7.7 93.1 ± 10.6" 91.7 ± 11.1 93.2 _+ 8.8* 96.2 ± 12.4" 98.8 ± 15.3 90.3 ± 7.9 
CI (L/min • m 2) 1.94 ± 0.31 2.02 _ 0.4 2.04 +- 0.44 1.97 ± 0.26 2.3 +_ 0.3 2.17 +_ 0.26 2.18 ± 0.2 
SI (ml/m 2) 20.6 ± 3.1 24 ± 5.3* 24.7 ± 6.8* 25 ± 6.7* 28.9 ± 4.4* 27 ± 6.8 25.7 ± 4.9 
RVSWI (gin. m/m 2) 7.4 ± 2.1 6.9 _+ 2.8 7 ± 3.6 6.9 +_ 2.6 6.7 ± 1.4 7.3 ± 0.7 7.7 ± 0.7 
LVSWI (gin. m/m 2) 17.5 ± 5.2 25.5 +_ 9.1" 25.6 ± 9.4* 25.4 ± 7* 30.9 -+ 9.5* 29.7 ± 10.9" 25.5 ± 8.5 
PVR (dyne. sec- cm -s) 288 ± 166 271 ± 96 282 +_ 136 267 ± 94 183 ± 107 288 + 165 236 ± 70 
SVR (dyne. sec- cm -s) 1862 ± 258 1962 - 329 1882 ± 393 1930 ± 365 1748 ± 166 1838 ± 305 1638 ± 141 
MRAP, Mean right atrial pressure; MPAP, mean pulmonary artery pressure; MPWP, mean pulmonary wedge pressure; MAP, mean arterial pressure; C/, 
cardiac index; SI, systolic index; RVSWI, right ventricular stroke work index; LVSWI, left ventricular stroke work index; PVR, pulmonary vascular resistance; 
SVR, systemic vascular resistance. Numbers in parenthesis indicate the patients evaluated at each period. 
*p < 0.05 in relation to preoperative data of matched patients. 
previously published. 6' 9 More precisely, although 
left ventricular stroke volume and cardiac output 
augmentation at rest were modest after this opera- 
tion, the impact of cardiomyoplasty on circulatory 
function could be better evaluated by its significant 
influence on left ventricular stroke work and pulmo- 
nary pressures. In addition, more evident changes in 
cardiac output and global circulatory function dur- 
ing exercise have been clinically shown after this 
procedure. 17
The enhancement of ventricular function after 
cardiomyoplasty involves, furthermore, modifica- 
tions in the mechanical properties of the failing 
heart. Another study showed that the effects of 
synchronous skeletal muscle flap contraction on left 
ventricular systolic function also include the in- 
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crease of the maximal elastance and the decrease of 
the wall stress. TM Regarding the diastolic function, 
decreases in end-diastolic pressure, stress, and 
chamber and muscle stiffness were also noticed. 
Because left ventricular wall stress is an important 
determinant ofmyocardial oxygen consumption, the 
reduction in wall stress can reduce myocardial oxy- 
gen demand, as demonstrated experimentally, w' 20 
Accordingly, in a dilated, failing left ventricle, the 
primary pathophysiologic abnormalities 21'22 are 
partially corrected, and slow progression of the 
underlying cardiomyopathy can result from this 
mechanism. 
Maintenance of hemodynamic mprovement for 
up to 5 years after cardiomyoplasty in the present 
study seems to indicate that heart failure had 
stopped progressing in the surviving patients. How- 
ever, the tendency of left ventricular ejection frac- 
tion to decrease at late follow-up suggests that the 
effects of this procedure on heart failure may be 
limited to a mid-term period. Stabilization in the 
process of ventricular dilatation and maintenance of
normal hemodynamic parameters for more than 3 
years after this operation were also reported by 
Carpentier and coUeagues, ~ but their experience 
included mainly patients with ischemic ardiomyop- 
athy. 
Functional improvement. In addition to changes 
in ventricular function, the improvement in func- 
tional class after cardiomyoplasty in this series 
agrees with the general clinical experience with this 
procedure. 1-9 Most of our patients were in func- 
tional class I or II, and a significant decrease in the 
number of hospitalizations per patient per year was 
also found. 
The functional benefits of cardiomyoplasty also 
include a decrease in the patient's limitations for 
physical activities, food and sleep patterns, and 
social activities, as we previously demonstrated by 
quality of life assessment. 23 Improvement in exercise 
capacity was similarly shown by the treadmill exer- 
cise test both in Carpentier's experience I and in our 
experience .24 
Effects on survival. Despite the functional im- 
provement revealed in this investigation, late mor- 
tality after cardiomyoplasty was high. Heart failure 
progressed, especially in patients with important 
preoperative compromise or with evidence of skel- 
etal muscle flap ischemia in the immediate postop- 
erative period. 25 Sudden cardiac death was also 
observed, but it was less prevalent han that de- 
scribed in the literature--approximately 20% to 
30% per year in patients with chronic heart failure. 26 
Nevertheless, this complication is probably not af- 
fected by cardiomyoplasty and still needs effective 
treatment. 
It is important to emphasize that the current 
indications for cardiomyoplasty included mainly pa- 
tients at high risk of dying within 1 year, because 
they did not essentially differ from patients awaiting 
heart transplantation. 27 Moreover, we 1° already re- 
ported that the survival after this operation was 
much more favorable than the survival of a compa- 
rable, but not randomized, group of patients main- 
tained on medical therapy. In that study, patients 
undergoing to cardiomyoplasty had a survival of 
65% at 2 years of follow-up, whereas the 2-year 
survival was only 27% in the medically treated 
group. 
Also of interest is the fact that the mortality after 
cardiomyoplasty in this series was significantly 
higher in patients who were in functional class IV or 
who had elevated pulmonary vascular resistance, 
which suggests that the degree of cardiac function 
impairment before the operation plays an important 
role in the long-term outcome. Other studies also 
showed the impact of these factors on cardiomyo- 
plasty results, 1'5 and additional risk factors influenc- 
ing perioperative and late mortality after this pro- 
cedure have been similarly reported. 1'4. 25 Furnary 
and associates 4 observed a significant influence of 
right ventricular ejection fraction on early mortality 
after cardiomyoplasty, and Carpentier and col- 
leagues 1 described the importance of surgical fac- 
tors and of atrial fibrillation for hospital and late 
outcomes. 
Application of these findings to patient selection 
criteria may improve the benefits of cardiomyo- 
plasty. In this regard, patients operated on in func- 
tional class III in this series had survivals of 76% at 
2 years and of 59% from 3 to 5 years of follow-up. 
These values positively contrast with the recent 
reports of heart failure treatment with angiotensin- 
converting enzyme inhibitors or vasodilators, which 
showed a survival probability of only 40% in 5 years 
for patients in class III. 28' 29 Furthermore, the sur- 
vival expectation may be even worse in the presence 
of persistent abnormalities of hemodynamic profile, 
as documented in the preoperative period in most of 
the patients in this investigation. 3°-32 
Postoperative muscle flap performance. Besides 
preoperative factors, cardiomyoplasty outcome may 
also be influenced by technical aspects and by 
skeletal muscle flap response to electrical stimula- 
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tion. The use of right 8 or left latissimus dorsi muscle 
and the influence of the extent of the wrap around 
the heart 2remain controversial. 
Also important are the possibility of perioperative 
ischemic ompromise of the muscle flap 9 and the 
fact that the distal part of the latissimus dorsi muscle 
may eventually become fibrotic and atrophic. 33 
These region-specific changes were found in clinical 
cases by necropsy studies and by magnetic reso- 
nance images, 34 but their influence on long-term 
performance of the muscle flap remains unclear. 
The possible relationship between these findings 
and the late modifications ofleft ventricular ejection 
fraction in the present study suggests, however, the 
necessity of further investigations regarding the 
prevention of muscle flap ischemia nd the optimal 
stimulation protocols for transformation a d assis- 
tance. 
Study limitations. This report describes the long- 
term effects of cardiomyoplasty on left ventricular 
function. Nevertheless, the number of individuals 
was not sufficiently arge for statistical validation of 
data at 4 and 5 years of follow-up. The decreasing 
number of patients with time was inevitable, espe- 
cially as a result of the late deaths. 
Regarding the clinical outcome of cardiomyo- 
plasty, this study strongly suggested that this opera- 
tion may improve long-term survival of patients with 
severe cardiomyopathies who remain in functional 
class III despite maximal medical therapy. However, 
this finding was based only on data obtained in the 
literature. Also important was the fact that the 
analysis of preoperative factors associated with out- 
come was limited by the number of patients in this 
series, indicating that it will require further valida- 
tion. 
Conclusions 
Despite many controversies about this surgical 
procedure, the present experience with dynamic 
cardiomyoplasty demonstrated that it improves left 
ventricular function, ameliorates congestive heart 
failure, and is a low-risk operation in patients with 
idiopathic dilated cardiomyopathy. Furthermore, 
the long-term course of the surviving patients after 
cardiomyoplasty seems to be characterized by the 
stabilization of the underlying disease for up to 5 
years of follow-up. 
Although long-term survival after this operation 
may be limited by the severity of the patient's 
preoperative condition, this procedure seems other- 
wise to be a promising alternative to the treatment 
of advanced heart failure in patients in functional 
class III or reversible class IV who also have mild or 
moderate pulmonary hypertension. Further studies 
are needed, however, to improve technical aspects 
and to confirm these observations with data from a 
larger, randomized clinical trial, comparing car- 
diomyoplasty and medical therapy outcomes. 
We are grateful for the kind collaboration of Mrs. 
Creusa M. Roveri Del B6, consultant s atistician. 
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Discussion 
Dr. George J. Magovern (Pittsburgh, Pa.). We have 
performed the cardiomyoplasty procedure on approxi- 
mately 38 patients at Allegheny General Hospital. Our 
first five patients were out of protocol, but they were 
good-risk patients. Three of the five are still alive with 
dramatically improved ejection fractions. 
We then began using the Food and Drug Administra- 
tion protocol, and we had a 30% operative mortality. I 
believe nine of the patients died of arrhythmia, with one 
current survivor. They were mostly ischemic patients who 
had been candidates for transplantation. 
The third group, comprising 15 patients, was also in a 
Food and Drug Administration protocol. Our results at 2 
years parallel the results reported by Dr. Moreira's group. 
Dr. Moreira, did you do all your cases through a left 
thoracotomy or did you use a combined approach? The 
duration of the operative procedure is probably critical. 
Have you compared any primary cardiomyopathy cases 
with ischemic cardiomyopathy cases? We believe it is 
critical to preserve the muscle, and we are considering a 
2-week delay in the procedure, after the muscle is freed, to 
allow for the development of collaterals. 
We have noticed that if we stop the stimulation for say 
a 2-week period and then restart it, the ejection fraction 
improves. Have you ever turned the pacer off and let the 
muscle wrap rest and relax? 
Our first group of patients had no operative mortality, 
and four of five survived. It is unique that in two of the 
patients who are still living the ejection fraction has 
remained significantly improved. 
Dr. Moreira: Dr. Magovern, thank you very much for 
your comments. Regarding your first question, we used 
two incisions, a lateral approach for muscle flap dissection 
and a subsequent sternotomy for the heart procedure. 
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This operation takes about 8 hours, and I do not think that 
its length is a critical problem. 
The sudden cardiac deaths in this series occurred 
especially in patients with important arrhythmias. I be- 
lieve this problem may be even more important in isch- 
emic patients. 
Regarding muscle flap preservation, I think we need to 
study better how to decrease the skeletal muscle ischemic 
compromise in the cardiomyoplasty procedure. Further- 
more, we need to evaluate better stimulation patterns to 
achieve a more powerful muscle flap contraction i  the 
long term, without late compromise of the skeletal muscle 
function and integrity. Regarding the muscle flap synchro- 
nization ratio, we used both the 2:1 and 1:1 modes. Most 
of our patients had better results with the 1:1 mode. 
Otherwise, I believe that the idea of stopping the muscle 
stimulation for some time at night may be beneficial and 
may need to be investigated. 
Dr. John M. Kratz (Charleston, S.C.). Your data seem 
to suggest some late problem with the whole procedure 
and a tailing off of benefits. Our laboratory work and that 
of others have also suggested later problems with the 
muscle, such as fibrosis. Did you have the opportunity to 
do any autopsies on patients dying in the late postopera- 
tive period? What was the muscle like at that time? 
Dr. Moreira. We performed some autopsies and also 
studied some patients by means of magnet resonance 
imaging while the cardiomyostimulator was being re- 
placed. These patients were evaluated between 2 and 5 
years of follow-up. Most of then had some degree of 
fibrosis and fatty tissue infiltration in the latissimus dorsi 
muscle flap. On the other hand, it is important to empha- 
size that patients having magnet resonance imaging were 
also subjected to left ventricular function evaluation with 
the cardiomyostimulator turned on and off. These studies 
showed a significant decrease of left ventricular ejection 
fraction in some patients when the myostimulator was 
turned off, even in the presence of muscle flap fibrosis and 
fat tissue infiltration. 
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